Older patients with PAH who were at least 55 years old showed significantly smaller improvements in 6-minute walk distance.
This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello and welcome to this Medscape InDiscussion on pulmonary arterial hypertension (PAH). Our topic today is the very important ...
Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The ...
On March 26, 2024, the FDA approved WINREVAIR in the U.S. for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional ...
Benefit with sotatercept seen among adults with pulmonary arterial hypertension diagnosed less than a year earlier. (HealthDay News) — The addition of sotatercept, an activin-signaling inhibitor, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results